Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 23
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Eton Pharmaceuticals Inc
ETON
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$49.86
-0.16
-0.32%
Dern. MÀJ: Oct 23, 1:25 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Eton Pharmaceuticals Financials
Eton Pharmaceuticals (ETON) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Dow Falls Over 100 Points, Records Weekly Loss: Investor Sentiment Weakens, but Fear Index Remains in ‘Greed’ Zone
The Fear & Greed Index, which measures market sentiment, declined while remaining in the Greed zone. U.S. stocks closed lower, with the Dow Jones falling over 100 points.
Avi Kapoor
PRO
Eton Pharmaceuticals Q2 Adj. EPS $0.43 Beats $0.10 Estimate, Sales $37.568M Beat $27.119M Estimate
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.10 by 290.91 percent. This is a 530 percent increase over losses of $(0.10) per share
Benzinga Newsdesk
PRO
Eton Pharmaceuticals FY2026 Revenue expected to be more than $145.000M vs $121.326M Est
Eton Pharmaceuticals (NASDAQ:ETON) FY2026 Revenue expected to be more than $145.000M vs $121.326M Est
Benzinga Newsdesk
PRO
Eton Pharmaceuticals FY2026 Revenue expected to be more than $120.000M vs $113.804M Est
Eton Pharmaceuticals (NASDAQ:ETON) FY2026 Revenue expected to be more than $120.000M vs $113.804M Est
Benzinga Newsdesk
PRO
Eton Pharmaceuticals Q1 Adj. EPS $0.14 Beats $0.09 Estimate, Sales $24.266M Beat $22.312M Estimate
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.09 by 55.56 percent. This is a 100 percent increase over earnings of $0.07 per share from
Benzinga Newsdesk
Earnings Scheduled For May 14, 2026
Benzinga Insights
